HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carol Cronenberger Selected Research

PF-06410293

6/2022Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
1/2021Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
1/2021Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
1/2018A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carol Cronenberger Research Topics

Disease

7Rheumatoid Arthritis
06/2022 - 01/2018
2Hypersensitivity (Allergy)
01/2018 - 12/2013
2Alzheimer Disease (Alzheimer's Disease)
09/2017 - 12/2013
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020
1Injection Site Reaction
01/2018
1Myocardial Infarction
01/2018
1Opportunistic Infections (Opportunistic Infection)
01/2018
1Pneumonia (Pneumonitis)
01/2018
1Rheumatic Diseases (Rheumatism)
01/2018
1Headache (Headaches)
09/2017

Drug/Important Bio-Agent (IBA)

7Biosimilar PharmaceuticalsIBA
06/2022 - 01/2018
4PF-06410293IBA
06/2022 - 01/2018
4Adalimumab (Humira)FDA Link
06/2022 - 01/2018
2GP1111IBA
04/2020 - 01/2019
2Infliximab (Remicade)FDA Link
04/2020 - 01/2019
2Amyloid (Amyloid Fibrils)IBA
09/2017 - 12/2013
2ponezumabIBA
09/2017 - 12/2013
1Pharmaceutical PreparationsIBA
01/2020
1Bevacizumab (Avastin)FDA Link
01/2020
1Rituximab (Mabthera)FDA Link
11/2018
1Biological ProductsIBA
01/2018
1C-Reactive ProteinIBA
01/2018
1Methotrexate (Mexate)FDA LinkGeneric
01/2018
1Immunoglobulin G (IgG)IBA
12/2013
1AntibodiesIBA
12/2013

Therapy/Procedure

2Activities of Daily Living (ADL)
06/2022 - 01/2021
2Therapeutics
01/2021 - 04/2020
1Intravenous Infusions
12/2013